United Therapeutics Corp. (NASDAQ:UTHR)’s share price traded up 3.1% during mid-day trading on Wednesday . The stock traded as high as $114.86 and last traded at $114.27, with a volume of 354,343 shares changing hands. The stock had previously closed at $110.87.

Several equities analysts have recently issued reports on the company. Cowen and Company reiterated a “buy” rating on shares of United Therapeutics Corp. in a research report on Thursday, April 28th. Zacks Investment Research upgraded United Therapeutics Corp. from a “hold” rating to a “strong-buy” rating and set a $125.00 price target on the stock in a research report on Tuesday, July 5th. Ladenburg Thalmann cut United Therapeutics Corp. from a “buy” rating to a “neutral” rating in a research report on Friday, April 29th. Leerink Swann restated a “market perform” rating on shares of United Therapeutics Corp. in a report on Saturday, April 16th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a $122.00 target price (down from $150.00) on shares of United Therapeutics Corp. in a report on Monday, April 11th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. United Therapeutics Corp. presently has an average rating of “Hold” and an average price target of $133.70.

The company has a 50 day moving average of $109.46 and a 200 day moving average of $118.11. The firm has a market capitalization of $5.12 billion and a price-to-earnings ratio of 6.57.

United Therapeutics Corp. (NASDAQ:UTHR) last issued its earnings results on Thursday, April 28th. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.21 by $0.19. During the same period in the prior year, the business earned $2.55 EPS. The company had revenue of $369 million for the quarter, compared to analyst estimates of $395.02 million. The business’s revenue was up 12.7% compared to the same quarter last year. Equities analysts expect that United Therapeutics Corp. will post $14.17 EPS for the current year.

In other United Therapeutics Corp. news, CEO Martine A. Rothblatt sold 5,547 shares of the firm’s stock in a transaction that occurred on Thursday, April 28th. The shares were sold at an average price of $106.81, for a total transaction of $592,475.07. Following the completion of the sale, the chief executive officer now directly owns 5,787 shares in the company, valued at $618,109.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 5,546 shares of the firm’s stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $115.74, for a total transaction of $641,894.04. Following the sale, the chief executive officer now owns 5,786 shares of the company’s stock, valued at $669,671.64. The disclosure for this sale can be found here.

Other large investors recently modified their holdings of the company. State of Tennessee Treasury Department increased its stake in shares of United Therapeutics Corp. by 29.9% in the fourth quarter. State of Tennessee Treasury Department now owns 86,900 shares of the biotechnology company’s stock valued at $13,609,000 after buying an additional 20,000 shares during the period. TrimTabs Asset Management LLC increased its stake in shares of United Therapeutics Corp. by 1.9% in the fourth quarter. TrimTabs Asset Management LLC now owns 13,856 shares of the biotechnology company’s stock valued at $2,170,000 after buying an additional 258 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of United Therapeutics Corp. by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 138,293 shares of the biotechnology company’s stock valued at $21,660,000 after buying an additional 4,251 shares during the period. Matarin Capital Management LLC bought a new stake in shares of United Therapeutics Corp. during the fourth quarter valued at about $4,154,000. Finally, Globeflex Capital L P bought a new stake in shares of United Therapeutics Corp. during the fourth quarter valued at about $2,061,000.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.